SAEs Analysis 3: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons‐Random Effects Model
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% Crl)
Mono	comp	1.16 (0.84,1.63)	1.15 (0.84,1.58)	0.01 (‐0.01,0.03)
TNF		1.53 (0.92,2.59)	1.49 (0.92,2.40)	0.03 (0.00,0.07)
non‐TNF		1.19 (0.80,1.78)	1.18 (0.81,1.71)	0.01 (‐0.01,0.04)
TOFA		0.48 (0.23,1.05)	0.50 (0.24,1.05)	‐0.03 (‐0.04,0.00)
MTXMono		1.18 (0.95,1.48)	1.17 (0.96,1.45)	0.01 (0.00,0.02)
MTXnon‐TNF		1.07 (0.88,1.30)	1.06 (0.88,1.29)	0.00 (‐0.01,0.01)
MTXTNF		1.33 (0.91,2.00)	1.31 (0.91,1.91)	0.02 (0.00,0.05)
MTXTOFA		2.04 (1.03,4.41)	1.94 (1.03,3.77)	0.05 (0.00,0.14)
MTXANA		1.07 (0.64,1.83)	1.06 (0.65,1.75)	0.00 (‐0.02,0.04)
TNF	Mono	1.31 (0.72,2.43)	1.29 (0.74,2.26)	0.02 (‐0.02,0.07)
non‐TNF		1.02 (0.64,1.62)	1.02 (0.66,1.57)	0.00 (‐0.02,0.03)
TOFA		0.42 (0.18,0.96)	0.43 (0.20,0.96)	‐0.03 (‐0.06,0.00)
MTXMono		1.02 (0.70,1.48)	1.02 (0.72,1.45)	0.00 (‐0.02,0.02)
MTXnon‐TNF		0.92 (0.63,1.33)	0.92 (0.65,1.31)	0.00 (‐0.03,0.01)
MTXTNF		1.15 (0.71,1.91)	1.14 (0.72,1.83)	0.01 (‐0.02,0.04)
MTXTOFA		1.76 (0.82,4.06)	1.68 (0.83,3.50)	0.04 (‐0.01,0.13)
MTXANA		0.92 (0.50,1.72)	0.92 (0.52,1.66)	0.00 (‐0.03,0.03)
non‐TNF	TNF	0.78 (0.40,1.49)	0.79 (0.43,1.45)	‐0.02 (‐0.07,0.02)
TOFA		0.32 (0.13,0.81)	0.33 (0.14,0.82)	‐0.05 (‐0.10,‐0.01)
MTXMono		0.77 (0.44,1.35)	0.79 (0.47,1.33)	‐0.02 (‐0.06,0.02)
MTXnon‐TNF		0.70 (0.40,1.21)	0.72 (0.43,1.20)	‐0.02 (‐0.07,0.01)
MTXTNF		0.88 (0.53,1.44)	0.88 (0.56,1.40)	‐0.01 (‐0.05,0.02)
MTXTOFA		1.34 (0.56,3.36)	1.31 (0.59,2.95)	0.02 (‐0.04,0.12)
MTXANA		0.70 (0.33,1.47)	0.71 (0.36,1.43)	‐0.02 (‐0.07,0.02)
TOFA	non‐TNF	0.41 (0.18,0.97)	0.42 (0.19,0.97)	‐0.03 (‐0.07,0.00)
MTXMono		1.00 (0.64,1.56)	1.00 (0.66,1.52)	0.00 (‐0.03,0.02)
MTXnon‐TNF		0.90 (0.59,1.37)	0.90 (0.61,1.35)	‐0.01 (‐0.03,0.02)
MTXTNF		1.12 (0.65,1.98)	1.12 (0.66,1.90)	0.01 (‐0.03,0.04)
MTXTOFA		1.72 (0.78,4.10)	1.65 (0.80,3.54)	0.04 (‐0.02,0.13)
MTXANA		0.90 (0.47,1.74)	0.90 (0.49,1.68)	‐0.01 (‐0.04,0.03)
MTXMono	TOFA	2.44 (1.10,5.31)	2.36 (1.10,5.03)	0.03 (0.00,0.05)
MTXnon‐TNF		2.21 (0.99,4.71)	2.14 (0.99,4.49)	0.03 (0.00,0.05)
MTXTNF		2.77 (1.17,6.34)	2.64 (1.16,5.90)	0.04 (0.01,0.07)
MTXTOFA		4.23 (1.49,12.66)	3.90 (1.46,10.72)	0.07 (0.02,0.17)
MTXANA		2.21 (0.87,5.50)	2.14 (0.88,5.16)	0.03 (‐0.01,0.07)
MTXnon‐TNF	MTXMono	0.90 (0.69,1.18)	0.91 (0.70,1.16)	‐0.01 (‐0.02,0.01)
MTXTNF		1.13 (0.72,1.78)	1.12 (0.73,1.70)	0.01 (‐0.02,0.04)
MTXTOFA		1.72 (0.87,3.74)	1.65 (0.87,3.22)	0.04 (‐0.01,0.13)
MTXANA		0.90 (0.52,1.61)	0.90 (0.53,1.56)	‐0.01 (‐0.03,0.03)
MTXTNF	MTXnon‐TNF	1.25 (0.81,1.96)	1.23 (0.82,1.87)	0.01 (‐0.01,0.04)
MTXTOFA		1.91 (0.94,4.22)	1.82 (0.95,3.62)	0.04 (0.00,0.14)
MTXANA		1.00 (0.57,1.77)	1.00 (0.59,1.70)	0.00 (‐0.02,0.04)
MTXTOFA	MTXTNF	1.53 (0.69,3.67)	1.48 (0.70,3.18)	0.03 (‐0.02,0.13)
MTXANA		0.80 (0.41,1.56)	0.81 (0.43,1.51)	‐0.01 (‐0.05,0.03)
MTXANA	MTXTOFA	0.52 (0.21,1.25)	0.55 (0.24,1.23)	‐0.04 (‐0.14,0.01)
Random‐Effect Model	Residual Deviance	128.1 vs 122 data points
	Deviance Information Criteria	680.036
Fixed‐Effect Model	Residual Deviance	136.1 vs 122 data points
	Deviance Information Criteria	680.533
Note:
Total Patients	25872
Total Studies	58
2‐arm	52
3‐arm	6